Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer
September 01 2021 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced the appointment of Dr. Kristen K. Buck as the
Company’s Chief Medical Officer (“CMO”).
Dr. Buck joins Caladrius from ICON plc (“ICON”), a global
provider of drug and device development and commercialization
services to the pharmaceutical, biotechnology and medical device
industries. During her time at ICON, Dr. Buck served as its CMO,
where she represented the company’s position on key scientific,
ethical, and medical governance matters, provided guidance and
oversight to the medical and scientific groups, and led the Drug
Development Services group. Prior to that, she was Senior Vice
President & Chief of Clinical Development at Optum Insights
(part of the United Healthcare Group) where she led the clinical
operations and regulatory groups within the Digital Research
Network (DRN) clinical trial business. Dr. Buck brings extensive
drug development experience in multiple therapeutic indications
including cardiovascular/metabolic, rare diseases,
gastrointestinal, neuroscience, oncology, immunology, and women’s
health.
“We are delighted to welcome Dr. Buck to Caladrius,” said David
J. Mazzo, PhD, President and Chief Executive Officer of Caladrius.
“Kristen’s wealth of knowledge and extensive medical, drug/device,
regulatory, and safety expertise across many therapeutic areas will
prove instrumental during the Company’s evolution as we continue to
advance and expand our clinical development programs and execute
upon our vision.”
Dr. Buck is a board certified and licensed physician who
received her medical degree from the Pennsylvania State University
School of Medicine and completed her internship and residency
in Internal Medicine at Abington Memorial Hospital before working
in private practice as a primary care physician. Subsequently,
she moved to the U.S. Food and Drug Administration’s Office of New
Drugs Division of Gastrointestinal and Hematology Drug Products
where she was responsible for reviewing efficacy and safety data
for all new indications, as well as post-marketing safety data for
over 40 drugs. Earlier in her career Dr. Buck worked at AstraZeneca
where she served as a Global Safety Physician and Global Study
Physician. Dr. Buck also held a position at Quintiles/IQVIA as VP
Global Strategic Drug Development designing clinical development
plans and protocols across all therapeutic areas for emerging
biotech and large pharma.
“Caladrius is in a unique position. I believe this is an
exciting time to join the Company with several key milestones on
its horizon. As Chief Medical Officer, my primary objective will be
to lead the Company’s clinical development in a scientifically
rigorous manner that will result in clinical, regulatory and
commercial success,” said Dr. Buck. “Caladrius’ CD34+ cell therapy
technology has the potential to revolutionize the treatment of
ischemic diseases, and I am pleased to be joining such a talented
and dedicated team to create value for shareholders while bringing
innovative treatments to patients in need.”
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study (www.freedom-trial.com) in the U.S.
for the treatment of coronary microvascular dysfunction (“CMD”);
CLBS12 (HONEDRA® in Japan), recipient of orphan designation
for Buerger’s Disease in the U.S. and, in Japan, recipient of a
SAKIGAKE designation and eligible for early conditional approval
for the treatment of critical limb ischemia (“CLI”) and Buerger’s
Disease based on the results of an ongoing clinical trial; and
CLBS201, designed to assess the safety and efficacy of CD34+ cell
therapy as a treatment for diabetic kidney disease (“DKD). For
more information on the Company, please
visit www.caladrius.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than
statements of historical fact contained in this press release are
forward-looking statements including, without limitation, any
expectations of revenues, expenses, cash flows, earnings or losses
from operations, cash required to maintain current and planned
operations, capital or other financial items; any statements of the
plans, strategies and objectives of management for future
operations; market and other conditions; any plans or expectations
with respect to product research, development and
commercialization, including regulatory approvals; any other
statements of expectations, plans, intentions or beliefs; and any
statements of assumptions underlying any of the foregoing. Without
limiting the foregoing, the words “plan,” “project,” “forecast,”
“outlook,” “intend,” “may,” “will,” “expect,” “likely,” “believe,”
“could,” “anticipate,” “estimate,” “continue” or similar
expressions or other variations or comparable terminology are
intended to identify such forward-looking statements, although some
forward-looking statements are expressed differently. Factors that
could cause future results to differ materially from the recent
results or those projected in forward-looking statements include
the “Risk Factors” described in the Company’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (“SEC”) on
February 25, 2021 and in the Company’s other periodic filings with
the SEC. The Company’s further development is highly dependent on,
among other things, future medical and research developments and
market acceptance, which are outside of its control. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date of this Press Release.
Caladrius does not intend, and disclaims any obligation, to update
or revise any forward-looking information contained in this Press
Release or with respect to the matters described herein, except as
required by law.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryRachel GirardReal ChemistryPhone:
401-477-4030Email: rgirard@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2023 to Apr 2024